Last reviewed · How we verify
PLX-PAD high doses
At a glance
| Generic name | PLX-PAD high doses |
|---|---|
| Sponsor | Pluristem Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery (PHASE1, PHASE2)
- Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 (PHASE2)
- Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) (PHASE2)
- Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI) (PHASE1)
- Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLX-PAD high doses CI brief — competitive landscape report
- PLX-PAD high doses updates RSS · CI watch RSS
- Pluristem Ltd. portfolio CI